Embecta Corp.

Equities

EMBC

US29082K1051

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
10.31 ^USD	-0.87%		-2.92%	-45.54%

Feb. 09	Embecta Keeps Quarterly Dividend at $0.15 a Share, Payable March 15 to Shareholders as of Feb. 28	MT
Feb. 09	Sector Update: Health Care Stocks Mixed Pre-Bell Friday	MT

Embecta Corp. Updates Earnings Guidance for the Fiscal Year 2024

February 09, 2024 at 06:53 am EST

Embecta Corp. updated earnings guidance for the fiscal year 2024. For the year 2024, the company expected revenues to be $1,094 million to $1,116 million against $1,085 million to $1,105 million previous guidance.

Latest news about Embecta Corp.

Embecta Keeps Quarterly Dividend at $0.15 a Share, Payable March 15 to Shareholders as of Feb. 28	Feb. 09	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	Feb. 09	MT
Sector Update: Health Care	Feb. 09	MT
Transcript : Embecta Corp., Q1 2024 Earnings Call, Feb 09, 2024	Feb. 09
Embecta's Fiscal Q1 Adjusted Earnings Decline, Revenue Rises; Fiscal 2024 Guidance Lifted	Feb. 09	MT
Embecta Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 09	CI
Embecta Corp. Updates Earnings Guidance for the Fiscal Year 2024	Feb. 09	CI
(EMBC) EMBECTA Forecasts Fiscal Year 2024 EPS Range $1.95 - $2.15	Feb. 09	MT
Earnings Flash (EMBC) EMBECTA Posts Q1 Revenue $277.3M	Feb. 09	MT
Earnings Flash (EMBC) EMBECTA Posts Q1 EPS $0.61	Feb. 09	MT
North American Morning Briefing : Stock Futures Rise; S&P 500 Again Tests 5,000 Milestone	Feb. 09	DJ
Embecta Corp. Declares Quarterly Cash Dividend, Payable on March 15, 2024	Feb. 09	CI
Embecta Corp. Seeks M&A	Jan. 10	CI
Transcript : Embecta Corp. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 02:15 PM	Jan. 10
Embecta Submits Premarket Filing to FDA for Insulin Patch Pump	Jan. 09	MT
Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch Pump	Jan. 09	CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Dec. 01	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	Dec. 01	MT
Embecta Says Its Syringes Are Not Affected by US FDA Safety Warning	Dec. 01	MT
Morgan Stanley Adjusts Price Target on to $16 From $15, Maintains Underweight Rating	Nov. 22	MT
Transcript : Embecta Corp., Q4 2023 Earnings Call, Nov 21, 2023	Nov. 21
North American Morning Briefing : All Eyes on -2-	Nov. 21	DJ
Embecta Keeps Quarterly Dividend of $0.15 a Share, Payable Dec. 15 to Shareholders as of Dec. 4	Nov. 21	MT
(EMBC) EMBECTA Expects Fiscal Year 2024 EPS Range $1.90 - $2.10	Nov. 21	MT
Earnings Flash (EMBC) EMBECTA Posts Q4 Revenue $281.9M	Nov. 21	MT

Chart Embecta Corp.

Duration

Period

More charts

Company Profile

Embecta Corp. is a global medical device company. The Company is focused on providing solutions to people living with diabetes. The Company has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. The Company also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through a variety of channels, including retail, hospitals, pharmacies and other institutional channels.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-08 - Q2 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Embecta Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

10.31 USD

Average target price

16.5 USD

Spread / Average Target

+60.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
EMBECTA CORP.	-45.54%	594M
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution